AtriCure Inc
NASDAQ:ATRC

Watchlist Manager
AtriCure Inc Logo
AtriCure Inc
NASDAQ:ATRC
Watchlist
Price: 30.52 USD 0.07%
Market Cap: 1.5B USD
Have any thoughts about
AtriCure Inc?
Write Note

AtriCure Inc
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

AtriCure Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
AtriCure Inc
NASDAQ:ATRC
Pre-Tax Income
-$37.8m
CAGR 3-Years
N/A
CAGR 5-Years
-11%
CAGR 10-Years
-9%
Becton Dickinson and Co
NYSE:BDX
Pre-Tax Income
$2B
CAGR 3-Years
6%
CAGR 5-Years
12%
CAGR 10-Years
3%
Boston Scientific Corp
NYSE:BSX
Pre-Tax Income
$2.2B
CAGR 3-Years
20%
CAGR 5-Years
17%
CAGR 10-Years
36%
Stryker Corp
NYSE:SYK
Pre-Tax Income
$4.2B
CAGR 3-Years
24%
CAGR 5-Years
13%
CAGR 10-Years
14%
Abbott Laboratories
NYSE:ABT
Pre-Tax Income
$6.8B
CAGR 3-Years
-6%
CAGR 5-Years
12%
CAGR 10-Years
11%
Intuitive Surgical Inc
NASDAQ:ISRG
Pre-Tax Income
$2.4B
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
15%
No Stocks Found

AtriCure Inc
Glance View

Market Cap
1.5B USD
Industry
Health Care

Nestled in the heart of the highly competitive medical device industry, AtriCure Inc. has carved a significant niche for itself by focusing on the surgical treatment of atrial fibrillation, a common and potentially serious heart rhythm disorder. Founded in 2000 and headquartered in Mason, Ohio, AtriCure designs, manufactures, and sells an array of surgical devices aimed at improving treatment outcomes for this condition. The company’s innovative technology targets the complex network of electrical signals in the heart to restore regular rhythm and mitigate the risk of stroke—a common consequence of untreated atrial fibrillation. By providing surgeons with minimally invasive tools and advanced cryoablation and radiofrequency therapy systems, AtriCure not only addresses surgical efficiency but also enhances patient recovery times, distinguishing itself from its competitors. AtriCure derives its revenue from the sale of these sophisticated products directly to hospitals and surgical centers both in the United States and internationally. Key components of its portfolio include the Synergy Ablation System, which is acclaimed for its precision in creating lesions that block erratic electrical pathways, and AtriClip, a line of devices designed to occlude the left atrial appendage, thereby reducing stroke risk. As healthcare providers increasingly recognize the benefits of surgical intervention for atrial fibrillation over alternative treatments, AtriCure's financial health is buoyed by the rising adoption of its products. The company's strategic focus on expanding its product pipeline and enhancing its global sales footprint underscores its commitment to continuous growth and innovation in cardiac care.

ATRC Intrinsic Value
51 USD
Undervaluation 40%
Intrinsic Value
Price

See Also

What is AtriCure Inc's Pre-Tax Income?
Pre-Tax Income
-37.8m USD

Based on the financial report for Sep 30, 2024, AtriCure Inc's Pre-Tax Income amounts to -37.8m USD.

What is AtriCure Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-9%

Over the last year, the Pre-Tax Income growth was -55%.

Back to Top